| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.2 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.064 | 0.2 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.064 | 0.2 |
| mRNA | AZD6244 | FIMM | pan-cancer | AAC | -0.21 | 0.2 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.088 | 0.2 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.078 | 0.2 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | -0.074 | 0.2 |
| mRNA | tretinoin:carboplatin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.051 | 0.2 |